Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm By: Bragar Eagel & Squire via GlobeNewswire June 19, 2023 at 21:00 PM EDT NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSE: AI), Ascendis Pharma A/S (NASDAQ: ASND), Alvotech SA (NASDAQ: ALVO), and Shift4 Payments, Inc. (NYSE: FOUR). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. C3.ai, Inc. (NYSE: AI) On April 4, 2023, Kerrisdale Capital ("Kerrisdale") sent a letter to C3.ai's auditor, Deloitte & Touche, alleging "serious accounting and disclosure issues." Kerrisdale's letter "discuss[ed] the highly conspicuous growth in unbilled receivables to levels we've never before seen in software companies. Opaque, confusing and highly concerning disclosures and financials related to the company's related party and very large customer, Baker Hughes (BKR)." On this news, C3.ai's price fell $8.92 per share, or 26.34%, to close at $24.95 per share on April 3, 2023. For more information on the C3.ai investigation go to: https://bespc.com/cases/AI Ascendis Pharma A/S (NASDAQ: ASND) On April 3, 2023, Ascendis issued a press release "announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter." On this news, Ascendis's American depositary receipt ("ADR") price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023. For more information on the Ascendis investigation go to: https://bespc.com/cases/ASND Alvotech SA (NASDAQ: ALVO) On April 13, 2023, Alvotech issued a press release "announc[ing]…that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved." On this news, Alvotech's stock price fell sharply during intraday trading on April 14, 2023. For more information on the Alvotech investigation go to: https://bespc.com/cases/ALVO Shift4 Payments, Inc. (NYSE: FOUR) On April 19, 2023, Blue Orca Capital issued a report on Shift4 Payments, Inc., alleging that the Company “engaged in a string of highly questionable and hyper aggressive accounting maneuvers seemingly designed to keep the stock afloat, from cash flow manipulation to inexplicable distributor acquisitions that enabled it to capitalize a major component of COGS.” The report also alleges that “Shift4’s CFO abruptly left the Company the day before its Q2 2022 earnings call, amidst a lengthy string of correspondence with the SEC over its accounting. Its auditor warned of a material weakness over internal controls the very next quarter, just as it spent $256.4 million in a string of M&A that enabled it to capitalize a material share of COGS.” Shares of Shift4 Payments stock dropped more than 12% in intraday trading on April 19, 2023. For more information on the Shift4 investigation go to: https://bespc.com/cases/FOUR About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm By: Bragar Eagel & Squire via GlobeNewswire June 19, 2023 at 21:00 PM EDT NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSE: AI), Ascendis Pharma A/S (NASDAQ: ASND), Alvotech SA (NASDAQ: ALVO), and Shift4 Payments, Inc. (NYSE: FOUR). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. C3.ai, Inc. (NYSE: AI) On April 4, 2023, Kerrisdale Capital ("Kerrisdale") sent a letter to C3.ai's auditor, Deloitte & Touche, alleging "serious accounting and disclosure issues." Kerrisdale's letter "discuss[ed] the highly conspicuous growth in unbilled receivables to levels we've never before seen in software companies. Opaque, confusing and highly concerning disclosures and financials related to the company's related party and very large customer, Baker Hughes (BKR)." On this news, C3.ai's price fell $8.92 per share, or 26.34%, to close at $24.95 per share on April 3, 2023. For more information on the C3.ai investigation go to: https://bespc.com/cases/AI Ascendis Pharma A/S (NASDAQ: ASND) On April 3, 2023, Ascendis issued a press release "announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter." On this news, Ascendis's American depositary receipt ("ADR") price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023. For more information on the Ascendis investigation go to: https://bespc.com/cases/ASND Alvotech SA (NASDAQ: ALVO) On April 13, 2023, Alvotech issued a press release "announc[ing]…that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved." On this news, Alvotech's stock price fell sharply during intraday trading on April 14, 2023. For more information on the Alvotech investigation go to: https://bespc.com/cases/ALVO Shift4 Payments, Inc. (NYSE: FOUR) On April 19, 2023, Blue Orca Capital issued a report on Shift4 Payments, Inc., alleging that the Company “engaged in a string of highly questionable and hyper aggressive accounting maneuvers seemingly designed to keep the stock afloat, from cash flow manipulation to inexplicable distributor acquisitions that enabled it to capitalize a major component of COGS.” The report also alleges that “Shift4’s CFO abruptly left the Company the day before its Q2 2022 earnings call, amidst a lengthy string of correspondence with the SEC over its accounting. Its auditor warned of a material weakness over internal controls the very next quarter, just as it spent $256.4 million in a string of M&A that enabled it to capitalize a material share of COGS.” Shares of Shift4 Payments stock dropped more than 12% in intraday trading on April 19, 2023. For more information on the Shift4 investigation go to: https://bespc.com/cases/FOUR About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSE: AI), Ascendis Pharma A/S (NASDAQ: ASND), Alvotech SA (NASDAQ: ALVO), and Shift4 Payments, Inc. (NYSE: FOUR). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. C3.ai, Inc. (NYSE: AI) On April 4, 2023, Kerrisdale Capital ("Kerrisdale") sent a letter to C3.ai's auditor, Deloitte & Touche, alleging "serious accounting and disclosure issues." Kerrisdale's letter "discuss[ed] the highly conspicuous growth in unbilled receivables to levels we've never before seen in software companies. Opaque, confusing and highly concerning disclosures and financials related to the company's related party and very large customer, Baker Hughes (BKR)." On this news, C3.ai's price fell $8.92 per share, or 26.34%, to close at $24.95 per share on April 3, 2023. For more information on the C3.ai investigation go to: https://bespc.com/cases/AI Ascendis Pharma A/S (NASDAQ: ASND) On April 3, 2023, Ascendis issued a press release "announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter." On this news, Ascendis's American depositary receipt ("ADR") price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023. For more information on the Ascendis investigation go to: https://bespc.com/cases/ASND Alvotech SA (NASDAQ: ALVO) On April 13, 2023, Alvotech issued a press release "announc[ing]…that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved." On this news, Alvotech's stock price fell sharply during intraday trading on April 14, 2023. For more information on the Alvotech investigation go to: https://bespc.com/cases/ALVO Shift4 Payments, Inc. (NYSE: FOUR) On April 19, 2023, Blue Orca Capital issued a report on Shift4 Payments, Inc., alleging that the Company “engaged in a string of highly questionable and hyper aggressive accounting maneuvers seemingly designed to keep the stock afloat, from cash flow manipulation to inexplicable distributor acquisitions that enabled it to capitalize a major component of COGS.” The report also alleges that “Shift4’s CFO abruptly left the Company the day before its Q2 2022 earnings call, amidst a lengthy string of correspondence with the SEC over its accounting. Its auditor warned of a material weakness over internal controls the very next quarter, just as it spent $256.4 million in a string of M&A that enabled it to capitalize a material share of COGS.” Shares of Shift4 Payments stock dropped more than 12% in intraday trading on April 19, 2023. For more information on the Shift4 investigation go to: https://bespc.com/cases/FOUR About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
